Any potential subject who meets any of the following criteria will be excluded from participating in the trial.
- Primary central nervous system (CNS) lymphoma or known CNS involvement at screening, unless treated and stable for ≥3 months with no need for steroids or anti-epileptic medications.
- Prior solid-organ transplantation.
- Prior treatment with allogenic stem cell transplant ≤6 months before the first dose of study drug, has evidence of graft versus host disease, or requires immunosuppressant therapy.
- Autologous HSCT within 3 months before the first dose of ETH-155008.
- Active autoimmune disease within the past 2 years requires systemic immunosuppressive medications (ie, chronic corticosteroid, methotrexate, or tacrolimus).
- Toxicities from previous anti-cancer therapies have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy.
-
Has known past or current malignancy other than inclusion diagnosis, except for:
- Cervical carcinoma of Stage 1B or less.
- Non-invasive basal cell or squamous cell skin carcinomas.
- Non-invasive, superficial bladder cancer.
- Prostate cancer with a current PSA level < 0.1 ng/mL.
- malignancy which in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 1 year before the first dose of study drug.
- Any curable cancer with a CR of > 2 years duration.
- Prior treatment with a CDK4/6 or Pim inhibitor.
- Known allergies, hypersensitivity, or intolerance to ETH-155008 or its excipients.
- Prior chemotherapy within 3 weeks prior to first treatment, targeted therapy, immunotherapy, radiotherapy, or treatment with an investigational anticancer agent (including investigational vaccines) within 2 weeks before the first administration of ETH-155008. For investigational agents where half-life is known, there should be a treatment-free window of at least 2 weeks or 5 half-lives.
-
Corticosteroids >10 mg daily prednisone equivalents:
• A short course (ie, >10 mg daily prednisone equivalents for less than 7 days) of corticosteroids is permitted. Inhaled or topical steroids, and adrenal replacement doses ≤10 mg daily prednisone equivalents, are permitted in the absence of active autoimmune disease.
• If corticosteroids were used to treat immune-related adverse events associated with prior therapy, ≥7 days must have elapsed since the last dose of corticosteroid.
- History of clinically significant cardiovascular disease within the 6 months prior to the first dose of study drug including, but not limited to:
- Myocardial infarction
- Severe or unstable angina
- Clinically significant cardiac arrhythmias
- Uncontrolled (persistent) hypertension: systolic blood pressure >159 mmHg; diastolic blood pressure >99 mmHg
- Stroke or transient ischemic attack
- Venous thromboembolic events (i.e., pulmonary embolism) within 1 month prior to the first dose of study drug; uncomplicated (Grade ≤2) deep vein thrombosis is not considered exclusionary.
- Congestive heart failure (New York Heart Association class III-IV)
- Pericarditis or clinically significant pericardial effusion
- Myocarditis
- Endocarditis 13. Clinically significant pulmonary compromise, particularly the need for supplemental oxygen to maintain adequate oxygenation.
14. Unable to swallow capsules or tablets or malabsorption syndrome, disease significantly affecting GI function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction. If any of these conditions exist, the site should discuss with the sponsor to determine subject eligibility.
15. Evidence of active viral, bacterial, or uncontrolled systemic fungal infection requiring parenteral treatment within 2 weeks before the first dose of study drug.
16. Active or chronic hepatitis B or hepatitis C infection.
• Hepatitis B infection is defined by a positive test for hepatitis B surface antigen (HBsAg), or HBsAg negative and positive for anti-hepatitis B core antigen (HBc) with or without anti-HBs.
• Hepatitis C infection is defined by a positive hepatitis C virus (HCV) ribonucleic acid (RNA).
17. Tested HIV positive at screening. 18. Trauma or major surgery (e.g., requiring general anesthesia) within 28 days prior to the first dose of study drug. Note: Subjects with planned surgical procedures to be conducted under local anesthesia may participate.
19. Any serious underlying medical or psychiatric condition (e.g., alcohol or drug abuse), dementia or altered mental status; or any issue that would impair the ability of the subject to receive or tolerate the planned treatment at the investigational site, to understand informed consent, or that in the opinion of the investigator would contraindicate the participation in the study or confound the protocol-specified assessments or results of the study.
20. Requires a prohibited medication that cannot be discontinued or substituted, or temporally interrupted during the study; see Section 6.6.2 for prohibited therapies.
21. Are currently taking or have previously taken a sensitive oral CYP3A4 substrate or an oral 3A4 substrate with narrow therapeutic window (an at least 5 x half-life washout will be required).
22. Are currently taking or have taken a potent CYP3A4 or p-glycoprotein inducer or inhibitors (inclusive of prescription and over-the-counter medication and/or herbal products). An at least 2-week (or at least 5 x half-life washout for long half-life products) will be required.